PL1912636T3 - N-(aryloamino)sulfonamidowe inhibitory mek - Google Patents
N-(aryloamino)sulfonamidowe inhibitory mekInfo
- Publication number
- PL1912636T3 PL1912636T3 PL06788078T PL06788078T PL1912636T3 PL 1912636 T3 PL1912636 T3 PL 1912636T3 PL 06788078 T PL06788078 T PL 06788078T PL 06788078 T PL06788078 T PL 06788078T PL 1912636 T3 PL1912636 T3 PL 1912636T3
- Authority
- PL
- Poland
- Prior art keywords
- arylamino
- mek
- sulfonamide inhibitors
- sulfonamide
- inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/64—Sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
- C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C311/08—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
- C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C311/09—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton the carbon skeleton being further substituted by at least two halogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
- C07C311/10—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of a saturated carbon skeleton containing rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/14—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of rings other than six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/21—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
- C07C311/28—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
- C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/36—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/18—One oxygen or sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/84—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/36—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/54—Nitrogen and either oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/30—Hetero atoms other than halogen
- C07D333/34—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US70181405P | 2005-07-21 | 2005-07-21 | |
US70671905P | 2005-08-08 | 2005-08-08 | |
US73163305P | 2005-10-28 | 2005-10-28 | |
EP06788078.1A EP1912636B1 (en) | 2005-07-21 | 2006-07-21 | N-(arylamino)-sulfonamide inhibitors of mek |
PCT/US2006/028326 WO2007014011A2 (en) | 2005-07-21 | 2006-07-21 | N-(arylamino)-sulfonamide inhibitors of mek |
Publications (1)
Publication Number | Publication Date |
---|---|
PL1912636T3 true PL1912636T3 (pl) | 2015-02-27 |
Family
ID=37683815
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL06788078T PL1912636T3 (pl) | 2005-07-21 | 2006-07-21 | N-(aryloamino)sulfonamidowe inhibitory mek |
Country Status (13)
Country | Link |
---|---|
EP (1) | EP1912636B1 (pl) |
KR (1) | KR101377688B1 (pl) |
AU (1) | AU2006272837B2 (pl) |
CA (1) | CA2618218C (pl) |
CY (1) | CY1118055T1 (pl) |
DK (1) | DK1912636T3 (pl) |
ES (1) | ES2481402T3 (pl) |
HK (1) | HK1134436A1 (pl) |
IL (1) | IL189201A (pl) |
MX (1) | MX2008002114A (pl) |
PL (1) | PL1912636T3 (pl) |
PT (1) | PT1912636E (pl) |
WO (1) | WO2007014011A2 (pl) |
Families Citing this family (93)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9095581B2 (en) | 2005-07-21 | 2015-08-04 | Ardea Biosciences, Inc. | Combinations of MEK inhibitors and Raf kinase inhibitors and uses thereof |
AR059339A1 (es) | 2006-02-09 | 2008-03-26 | Chugai Pharmaceutical Co Ltd | Derivados de la cumarina para trastornos proliferativos de celulas, composicion farmaceutica y agente terapeutico que los contiene |
CN101663279A (zh) * | 2007-01-19 | 2010-03-03 | 阿迪生物科学公司 | Mek抑制剂 |
CN103951658B (zh) | 2007-04-18 | 2017-10-13 | 辉瑞产品公司 | 用于治疗异常细胞生长的磺酰胺衍生物 |
AR066505A1 (es) * | 2007-05-11 | 2009-08-26 | Bayer Schering Pharma Ag | Derivados de fenilaminobenceno sustituidos de utilidad para el tratamiento de trastornos y enfermedades hiperproliferativos asociados con actividad quinasa extracelular mediada por mitogenos |
WO2009014100A1 (ja) | 2007-07-20 | 2009-01-29 | Chugai Seiyaku Kabushiki Kaisha | p27蛋白質誘導剤 |
CN103479604B (zh) * | 2007-07-30 | 2016-08-10 | 阿迪生物科学公司 | 作为mek抑制剂的包括多晶型物的n-(芳氨基)磺酰胺衍生物和组合物、其使用方法和制备方法 |
JP5479337B2 (ja) * | 2007-07-30 | 2014-04-23 | アルディア バイオサイエンス,インク. | Mek阻害剤およびrafキナーゼ阻害剤の組み合わせ、ならびにその使用 |
TWI481590B (zh) * | 2008-03-06 | 2015-04-21 | Ardea Biosciences Inc | 作為mek抑制劑之n-(芳胺基)磺醯胺(包括多晶型)衍生物及組合物,使用方法及其製備方法 |
US8044240B2 (en) | 2008-03-06 | 2011-10-25 | Ardea Biosciences Inc. | Polymorphic form of N-(S)-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide and uses thereof |
JP2011518786A (ja) * | 2008-04-14 | 2011-06-30 | アルデア バイオサイエンシズ,インコーポレイティド | 調製及び使用のための組成物及び方法 |
US20110039819A1 (en) * | 2008-04-22 | 2011-02-17 | Marion Hitchcock | Substituted phenoxybenzamides |
WO2010051933A2 (en) * | 2008-11-10 | 2010-05-14 | Bayer Schering Pharma Aktiengesellschaft | Substituted sulphonamido phenoxybenzamides |
US20110237592A1 (en) * | 2008-11-10 | 2011-09-29 | Bayer Schering Pharma Aktiengesellschaft | Substituted amido phenoxybenzamides |
WO2010068738A1 (en) | 2008-12-10 | 2010-06-17 | Dana-Farber Cancer Institute, Inc. | Mek mutations conferring resistance to mek inhibitors |
CN103948600A (zh) | 2009-03-11 | 2014-07-30 | 阿迪生物科学公司 | 用于治疗特定癌症的包含rdea119/bay869766的药物组合 |
ES2543608T3 (es) * | 2009-03-27 | 2015-08-20 | Ardea Biosciences, Inc. | Dihidropiridin sulfonamidas y dihidropiridin sulfamidas como inhibidores de MEK |
EP2488507B1 (en) * | 2009-10-13 | 2014-12-17 | Allostem Therapeutics LLC | Novel mek inhibitors, useful in the treatment of diseases |
CA2777430A1 (en) | 2009-10-21 | 2011-04-28 | Bayer Pharma Aktiengesellschaft | Substituted benzosulphonamides |
PE20121471A1 (es) | 2009-11-04 | 2012-11-01 | Novartis Ag | Derivados de sulfonamida heterociclicos utiles como inhibidores de mek |
CN108774237A (zh) | 2009-12-01 | 2018-11-09 | Abbvie 公司 | 新的三环化合物 |
EP2538943B1 (en) | 2010-02-25 | 2016-03-30 | Dana-Farber Cancer Institute, Inc. | Braf mutations conferring resistance to braf inhibitors |
KR20120139767A (ko) | 2010-03-09 | 2012-12-27 | 더 브로드 인스티튜트, 인코퍼레이티드 | 1차 암 요법에 대한 저항성을 갖는 또는 발달시키는 환자에서 암을 진단 및 치료하는 방법 |
PE20130191A1 (es) * | 2010-04-16 | 2013-02-21 | Bayer Ip Gmbh | Combinaciones que contienen 2, 3-dihidroimidazo[1, 2-c]quinazolina sustituida |
MX2013003695A (es) | 2010-10-01 | 2013-05-20 | Bayer Ip Gmbh | Combinaciones que contienen n-(2-arilamino) arilsulfonamida sustituida. |
CN102020651B (zh) | 2010-11-02 | 2012-07-18 | 北京赛林泰医药技术有限公司 | 6-芳基氨基吡啶酮甲酰胺mek抑制剂 |
EP3409278B8 (en) | 2011-07-21 | 2020-11-04 | Sumitomo Dainippon Pharma Oncology, Inc. | Heterocyclic protein kinase inhibitors |
EP2796455A4 (en) * | 2011-12-19 | 2015-08-19 | Sumitomo Chemical Co | PROCESS FOR PRODUCING SULFONATE |
CA2860676A1 (en) | 2012-01-09 | 2013-07-18 | Novartis Ag | Organic compositions to treat beta-catenin-related diseases |
CN103204827B (zh) | 2012-01-17 | 2014-12-03 | 上海科州药物研发有限公司 | 作为蛋白激酶抑制剂的苯并噻二唑化合物及其制备方法和用途 |
US20150141470A1 (en) | 2012-05-08 | 2015-05-21 | The Broad Institute, Inc. | Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy |
CN104394855A (zh) | 2012-05-31 | 2015-03-04 | 拜耳医药股份有限公司 | 用于测定肝细胞癌(hcc)患者的治疗的有效响应的生物标记 |
DK2909181T3 (da) | 2012-10-16 | 2017-11-20 | Tolero Pharmaceuticals Inc | PKM2-modulatorer og fremgangsmåder til anvendelse deraf |
WO2014133071A1 (ja) | 2013-02-27 | 2014-09-04 | 第一三共株式会社 | Mapkシグナル伝達経路を阻害する化合物に対する応答性を予測する方法 |
US9498532B2 (en) | 2013-03-13 | 2016-11-22 | Novartis Ag | Antibody drug conjugates |
MX2015012062A (es) | 2013-03-14 | 2016-05-05 | Tolero Pharmaceuticals Inc | Inhibidores de jak2 y alk2 y metodos para su uso. |
NZ710929A (en) | 2013-03-15 | 2018-02-23 | Novartis Ag | Antibody drug conjugates |
EP2848246A1 (en) | 2013-09-13 | 2015-03-18 | Bayer Pharma Aktiengesellschaft | Pharmaceutical compositions containing refametinib |
US10786578B2 (en) | 2014-08-05 | 2020-09-29 | Novartis Ag | CKIT antibody drug conjugates |
KR20170040249A (ko) | 2014-08-12 | 2017-04-12 | 노파르티스 아게 | 항-cdh6 항체 약물 접합체 |
US9993551B2 (en) | 2014-09-13 | 2018-06-12 | Novartis Ag | Combination therapies of EGFR inhibitors |
US20170209574A1 (en) | 2014-10-03 | 2017-07-27 | Novartis Ag | Combination therapies |
SG11201703464UA (en) | 2014-11-14 | 2017-05-30 | Novartis Ag | Antibody drug conjugates |
WO2016100882A1 (en) | 2014-12-19 | 2016-06-23 | Novartis Ag | Combination therapies |
LT3237418T (lt) | 2014-12-23 | 2019-05-10 | Novartis Ag | Triazolpirimidino junginiai ir jų panaudojimas |
KR20170129757A (ko) | 2015-03-25 | 2017-11-27 | 노파르티스 아게 | Fgfr4 억제제로서의 포르밀화 n-헤테로시클릭 유도체 |
EP3310813A1 (en) | 2015-06-17 | 2018-04-25 | Novartis AG | Antibody drug conjugates |
MA44334A (fr) | 2015-10-29 | 2018-09-05 | Novartis Ag | Conjugués d'anticorps comprenant un agoniste du récepteur de type toll |
US11883404B2 (en) | 2016-03-04 | 2024-01-30 | Taiho Pharmaceuticals Co., Ltd. | Preparation and composition for treatment of malignant tumors |
BR112018076443A2 (pt) | 2016-06-20 | 2019-04-09 | Novartis Ag | formas cristalinas de um composto de triazolopirimidina |
WO2017221092A1 (en) | 2016-06-20 | 2017-12-28 | Novartis Ag | Triazolopyridine compounds and uses thereof |
EP3472166A1 (en) | 2016-06-20 | 2019-04-24 | Novartis AG | Imidazopyrimidine compounds useful for the treatment of cancer |
EP3592868B1 (en) | 2017-03-06 | 2022-11-23 | Novartis AG | Methods of treatment of cancer with reduced ubb expression |
WO2018185618A1 (en) | 2017-04-03 | 2018-10-11 | Novartis Ag | Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment |
AR111651A1 (es) | 2017-04-28 | 2019-08-07 | Novartis Ag | Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación |
JP2020520665A (ja) | 2017-05-24 | 2020-07-16 | ノバルティス アーゲー | 抗体−サイトカイングラフト化タンパク質及び癌の治療における使用方法 |
WO2018215937A1 (en) | 2017-05-24 | 2018-11-29 | Novartis Ag | Interleukin-7 antibody cytokine engrafted proteins and methods of use in the treatment of cancer |
WO2018215938A1 (en) | 2017-05-24 | 2018-11-29 | Novartis Ag | Antibody-cytokine engrafted proteins and methods of use |
CN111867594A (zh) | 2018-03-19 | 2020-10-30 | 大鹏药品工业株式会社 | 包含烷基硫酸钠的药物组合物 |
AU2019247498A1 (en) | 2018-04-05 | 2020-11-26 | Sumitomo Pharma Oncology, Inc. | AXL kinase inhibitors and use of the same |
AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
JOP20210001A1 (ar) | 2018-07-10 | 2021-01-05 | Novartis Ag | مشتقات 3-(5- هيدروكسي -1- أوكسو أيزو إندولين -2- يل) بيبريدين -2، 6- دايون واستخدامها لمعالجة أمراض مرتبطة ببروتين ذات أصبع الزنك من عائلة (ikaros 2 (ikzf2 |
AU2018433575B2 (en) | 2018-07-25 | 2022-07-07 | Advanced Accelerator Applications Sa | Stable, concentrated radionuclide complex solutions |
WO2020021465A1 (en) | 2018-07-25 | 2020-01-30 | Advanced Accelerator Applications (Italy) S.R.L. | Method of treatment of neuroendocrine tumors |
KR20210038906A (ko) | 2018-07-26 | 2021-04-08 | 스미토모 다이니폰 파마 온콜로지, 인크. | 비정상적 acvr1 발현과 연관된 질환을 치료하는 방법 및 그에 사용하기 위한 acvr1 억제제 |
DK3837256T3 (da) | 2018-08-17 | 2023-05-30 | Novartis Ag | Ureaforbindelser og sammensætninger som smarca2/brm-atpase-hæmmere |
US20210346527A1 (en) | 2018-09-25 | 2021-11-11 | Advanced Accelerator Applications (Italy) Srl | Combination Therapy |
US20230053449A1 (en) | 2018-10-31 | 2023-02-23 | Novartis Ag | Dc-sign antibody drug conjugates |
WO2020128972A1 (en) | 2018-12-20 | 2020-06-25 | Novartis Ag | Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives |
US20220040324A1 (en) | 2018-12-21 | 2022-02-10 | Daiichi Sankyo Company, Limited | Combination of antibody-drug conjugate and kinase inhibitor |
JP2022520361A (ja) | 2019-02-12 | 2022-03-30 | スミトモ ダイニッポン ファーマ オンコロジー, インコーポレイテッド | 複素環式タンパク質キナーゼ阻害剤を含む製剤 |
MX2021009764A (es) | 2019-02-15 | 2021-09-08 | Novartis Ag | Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona sustituidos y usos de los mismos. |
EA202192019A1 (ru) | 2019-02-15 | 2021-11-02 | Новартис Аг | Производные 3-(1-оксо-5-(пиперидин-4-ил)изоиндолин-2-ил)пиперидин-2,6-диона и пути их применения |
WO2020188015A1 (en) | 2019-03-21 | 2020-09-24 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
EP3941463A1 (en) | 2019-03-22 | 2022-01-26 | Sumitomo Dainippon Pharma Oncology, Inc. | Compositions comprising pkm2 modulators and methods of treatment using the same |
AU2020300619A1 (en) | 2019-07-03 | 2022-01-27 | Sumitomo Pharma Oncology, Inc. | Tyrosine kinase non-receptor 1 (TNK1) inhibitors and uses thereof |
CN114761006A (zh) | 2019-11-08 | 2022-07-15 | Inserm(法国国家健康医学研究院) | 对激酶抑制剂产生耐药性的癌症的治疗方法 |
CN115175937A (zh) | 2019-12-20 | 2022-10-11 | 诺华股份有限公司 | 用于治疗骨髓纤维化和骨髓增生异常综合征的抗TIM-3抗体MBG453和抗TGF-β抗体NIS793与或不与地西他滨或抗PD-1抗体斯巴达珠单抗的组合 |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
EP4134081A1 (en) | 2020-04-10 | 2023-02-15 | Taiho Pharmaceutical Co., Ltd. | Cancer therapy using 3,5-disubstituted benzene alkynyl compound and mek inhibitor |
WO2021252920A1 (en) | 2020-06-11 | 2021-12-16 | Novartis Ag | Zbtb32 inhibitors and uses thereof |
JP2023531676A (ja) | 2020-06-23 | 2023-07-25 | ノバルティス アーゲー | 3-(1-オキソイソインドリン-2-イル)ピぺリジン-2,6-ジオン誘導体を含む投与レジメン |
CN116134027A (zh) | 2020-08-03 | 2023-05-16 | 诺华股份有限公司 | 杂芳基取代的3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途 |
AR123185A1 (es) | 2020-08-10 | 2022-11-09 | Novartis Ag | Compuestos y composiciones para inhibir ezh2 |
EP4204020A1 (en) | 2020-08-31 | 2023-07-05 | Advanced Accelerator Applications International S.A. | Method of treating psma-expressing cancers |
EP4204021A1 (en) | 2020-08-31 | 2023-07-05 | Advanced Accelerator Applications International S.A. | Method of treating psma-expressing cancers |
WO2022043556A1 (en) | 2020-08-31 | 2022-03-03 | Novartis Ag | Stable radiopharmaceutical composition |
TW202237119A (zh) | 2020-12-10 | 2022-10-01 | 美商住友製藥腫瘤公司 | Alk﹘5抑制劑和彼之用途 |
TW202304979A (zh) | 2021-04-07 | 2023-02-01 | 瑞士商諾華公司 | 抗TGFβ抗體及其他治療劑用於治療增殖性疾病之用途 |
AU2022257621A1 (en) | 2021-04-13 | 2023-11-23 | Nuvalent, Inc. | Amino-substituted heterocycles for treating cancers with egfr mutations |
AR125874A1 (es) | 2021-05-18 | 2023-08-23 | Novartis Ag | Terapias de combinación |
WO2023214325A1 (en) | 2022-05-05 | 2023-11-09 | Novartis Ag | Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors |
WO2024023666A1 (en) | 2022-07-26 | 2024-02-01 | Novartis Ag | Crystalline forms of an akr1c3 dependent kars inhibitor |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040171632A1 (en) | 1998-12-22 | 2004-09-02 | Gowan Richard Carleton | Combination chemotherapy |
ATE309205T1 (de) | 1999-01-13 | 2005-11-15 | Warner Lambert Co | Benzenesulfonamid-derivative und ihre verwendung als mek-inhibitoren |
US20060140872A1 (en) | 2003-02-26 | 2006-06-29 | Kowa Co., Ltd. | Novel signaling pathway for the production of inglammatory pain and neuropathy |
TW200505834A (en) | 2003-03-18 | 2005-02-16 | Sankyo Co | Sulfamide derivative and the pharmaceutical composition thereof |
US7538120B2 (en) | 2003-09-03 | 2009-05-26 | Array Biopharma Inc. | Method of treating inflammatory diseases |
PL1761528T3 (pl) * | 2004-06-11 | 2008-05-30 | Japan Tobacco Inc | Pochodne 5-amino-2,4,7-triokso-3,4,7,8-tetrahydro-2H-pirydo[2,3-D]pirymidyny i związki pokrewne do leczenia raka |
-
2006
- 2006-07-21 MX MX2008002114A patent/MX2008002114A/es active IP Right Grant
- 2006-07-21 CA CA2618218A patent/CA2618218C/en not_active Expired - Fee Related
- 2006-07-21 DK DK06788078.1T patent/DK1912636T3/da active
- 2006-07-21 WO PCT/US2006/028326 patent/WO2007014011A2/en active Application Filing
- 2006-07-21 EP EP06788078.1A patent/EP1912636B1/en active Active
- 2006-07-21 ES ES06788078.1T patent/ES2481402T3/es active Active
- 2006-07-21 PL PL06788078T patent/PL1912636T3/pl unknown
- 2006-07-21 AU AU2006272837A patent/AU2006272837B2/en not_active Ceased
- 2006-07-21 PT PT67880781T patent/PT1912636E/pt unknown
-
2008
- 2008-02-03 IL IL189201A patent/IL189201A/en not_active IP Right Cessation
- 2008-02-21 KR KR1020087004227A patent/KR101377688B1/ko active IP Right Grant
-
2010
- 2010-01-07 HK HK10100120.1A patent/HK1134436A1/xx not_active IP Right Cessation
-
2014
- 2014-07-16 CY CY20141100532T patent/CY1118055T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
AU2006272837B2 (en) | 2012-08-23 |
EP1912636A4 (en) | 2009-11-18 |
WO2007014011A2 (en) | 2007-02-01 |
CA2618218A1 (en) | 2007-02-01 |
IL189201A (en) | 2014-05-28 |
AU2006272837A1 (en) | 2007-02-01 |
CA2618218C (en) | 2015-06-30 |
DK1912636T3 (da) | 2014-07-21 |
CY1118055T1 (el) | 2017-06-28 |
ES2481402T3 (es) | 2014-07-30 |
IL189201A0 (en) | 2009-02-11 |
WO2007014011A3 (en) | 2009-04-23 |
KR20080068637A (ko) | 2008-07-23 |
EP1912636B1 (en) | 2014-06-25 |
HK1134436A1 (en) | 2010-04-30 |
EP1912636A2 (en) | 2008-04-23 |
KR101377688B1 (ko) | 2014-03-25 |
PT1912636E (pt) | 2014-07-24 |
MX2008002114A (es) | 2008-04-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1134436A1 (en) | N-(arylamino)-sulfonamide inhibitors of mek mek | |
ZA200802585B (en) | Pyridopyrimidinone inhibitors of Pl3Kα | |
IL190292A0 (en) | PYRIDOPYRIMIDINONE INHIBITORS OF P13Ka | |
ZA200610593B (en) | Diphenylimidazopyrimidine and -imidazole amines as inhibitors of ß-secretase | |
EP1756092A4 (en) | NEW INHIBITORS OF RHO-KINASEN | |
IL192134A0 (en) | Soft protease inhibitors and pro-soft forms thereof | |
IL179398A0 (en) | Dpp-ib inhibitors | |
ZA200802867B (en) | Fap inhibitors | |
DK2439205T3 (da) | Carboxamidforbindelser og deres anvendelse som calpaininhibitorer | |
HRP20130810T1 (en) | Sulphonylpyrroles as hdac inhibitors | |
ZA200801351B (en) | Sulphonypyrrole hydrochloride salts as histone deacetylases inhibitors | |
IL190372A0 (en) | Biaryl substituted heterocycle inhibitors of lta4h | |
EP1750696B1 (en) | RETROVIRAL PROTEASE INHIBITORS RESISTING THEIR RESISTANCE | |
HK1110579A1 (en) | New histone deacetylases inhibitors | |
EP1732891A4 (en) | RESISTANT PREVENTIVE INHIBITORS FOR RETROVIRAL PROTEASES | |
HK1099300A1 (en) | Substituted n-arylsulfonylheterocyclic amines as gamma-secretase inhibitors | |
EP1921078A4 (en) | MULTIKINASE INHIBITOR | |
GB0400290D0 (en) | dUTPase inhibitors | |
EP1910272A4 (en) | INHIBITORS OF THE RENINE | |
EP1789055A4 (en) | INHIBITORS OF THIAZOLOPYRIDINE KINASE | |
ZA200801443B (en) | N-(arylamino)-sulfonamide inhibitors of MEK | |
GB0515327D0 (en) | Comt inhibitors | |
GB0421355D0 (en) | Inhibitors | |
EP1912662A4 (en) | PEPTIDE DEFORMYLASE INHIBITORS | |
GB0421356D0 (en) | Inhibitors |